The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 6, 2016, Pages 1508-1519

  Mathavan, Sangeetha ^a   Chen Tan, Nigel ^b   Arfuso, Frank ^a   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

artificial cell microencapsulation; bile acids; chenodeoxycholic acid; diabetes; gliclazide

Indexed keywords

BODY FLUIDS; MEDICAL PROBLEMS; WATER ABSORPTION;

ANTI-DIABETIC DRUGS; ANTI-INFLAMMATORY EFFECTS; ARTIFICIAL CELL; BILE ACID; CHENODEOXYCHOLIC ACID; GLICLAZIDE; UNIFORM STRUCTURE; WATER SOLUBILITIES;

MICROSTRUCTURE;

ALGINIC ACID; CHENODEOXYCHOLIC ACID; GLICLAZIDE; PENETRATION ENHANCING AGENT; ANTIDIABETIC AGENT; GLUCURONIC ACID; HEXURONIC ACID; MICROCAPSULE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MELTING POINT; MICROCAPSULE; MICROENCAPSULATION; PH; SHEAR RATE; SHEAR STRESS; SURFACE PROPERTY; TORQUE; VISCOSITY; ZETA POTENTIAL; CHEMISTRY; DIABETES MELLITUS, TYPE 1; DRUG FORMULATION; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ALGINATES; CAPSULES; CHENODEOXYCHOLIC ACID; DIABETES MELLITUS, TYPE 1; DRUG COMPOUNDING; GLICLAZIDE; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84982958580     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2015.1058807     Document Type: Article

References (45)

1. F.Acartürk S.Takka. 1998. Calcium alginate microparticles for oral administration:II. Effect of formulation factors on drug release and drug entrapment efficiency. J Microencapsulation. 16:291–301.
2. R.S.Al-Kassas O.Al-Gohary, M.M.Al-Faadhel. 2007. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharma. 341:230–237.
3. H.Al-Salami G.Butt J.P.Fawcett I.G.Tucker S.Golocorbin-Kon, M.Mikov. 2008a. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 33:101–106.
4. H.Al-Salami, G.Butt, I.Tucker, P.J.Fawcett, S.Golo-Corbin-Kon, I.Mikov, M.Mikov. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Euro J Drug Metab Pharmacokinet. 34:43–50.
5. H.Al-Salami, G.Butt, I.Tucker, M.Mikov. 2008b. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 60:532–541.
6. H.Al-Salami, G.Butt, I.Tucker, M.Mikov. 2008c. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
7. H.Al-Salami, G.Butt, I.Tucker, M.Mikov. 2008d. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107–113.
8. H.Al-Salami, G.Butt, I.Tucker, R.Skrbic, S.Golocorbin-Kon, M.Mikov. 2008e. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. ArchDrug Inf. 1:35–41.
9. H.Al-Salami, G.Butt, I.G.Tucker, M.Mikov. 2008f. The Influence of Pre-Treatment with Probiotics on the in Vitro Ileal Permeation of the Antidiabetic Drug Gliclazide, in Healthy and Diabetic Rats. Drug Metabol Rev. 40:81–82.
10. N.S.Barakat, A.S.Almurshedi. 2011. Design and development of gliclazide‐loaded chitosan microparticles for oral sustained drug delivery:in‐vitro/in‐vivo evaluation. J Pharma Pharmacol. 63:169–178.
11. N.S.Barakat, G.A.Shazly, A.H.Almedany. 2013. Influence of polymer blends on the characterization of gliclazide–encapsulated into poly (epsilon-caprolactone) microparticles. Drug Dev Ind Pharm. 39:352–362.
12. J.Berger, M.Reist, J.M.Mayer, O.Felt, R.Gurny. 2004. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharma Biopharma. 57:35–52.
13. S.Biswal, J.Sahoo, P.Murthy. 2009. Characterisation of gliclazide-PEG 8000 solid dispersions. Tropical J Pharma Res. 8:417–424.
14. O.Borges, G.Borchard, J.C.Verhoef, A.De Sousa, H.E.Junginger. 2005. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharma. 299:155–166.
15. D.Campbellt, R.Laviellez, C.C.Nathan. 1991The mode of action and clinical pharmacology of gliclazide:A review. Diab Res Clin Prac. 14:26–31.
16. K.L.A.Chan, N.Elkhider, S.G.Kazarian. 2005. Spectroscopic Imaging of Compacted Pharmaceutical Tablets. Chem Eng Res Des. 83:1303–1310.
17. X.Chen, D.Yang W.Shen H.F.Dong, J.M.Wang, J.J.Oppenheim, M.Z.Howard. 2000. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res. 49:744–755.
18. P.Gill, T.T.Moghadam, B.Ranjbar. 2010. Differential scanning calorimetry techniques:applications in biology and nanoscience. J Biomol Tech. 21:167.
19. N.Goyal, A.Rana, K.Bijjem P.Kumar. 2015. Effect of chenodeoxycholic acid and sodium hydrogen sulfide in dinitro benzene sulfonic acid (DNBS) – Induced ulcerative colitis in rats. Pharmacol Rep. 67:616–623.
20. S.M.Houten M.Watanabe, J.Auwerx. 2006. Endocrine functions of bile acids. EMBO J. 25:1419–1425.
21. P.B.Hylemon, H.Zhou, W.M.Pandak, S.Ren, G.Gil, P.Dent. 2009. Bile acids as regulatory molecules. J Lipid Res. 50:1509–1520.
22. S.G.Kazarian, K.L.A.Chan. 2006. Applications of ATR-FTIR spectroscopic imaging to biomedical samples. Biochim Biophys Acta Biomembranes. 1758:858–867.
23. S.G.Kazarian, K.W.T.Kong, M.Bajomo, J.Van Der Weerd, K.L.A.Chan. 2005. Spectroscopic Imaging Applied to Drug Release. Food Bioprod Process. 83:127–135.
24. K.Kuhajda, J.Kandrac, S.Kevresan, M.Mikov, J.Fawcett. 2006. Structure and origin of bile acids:An overview. Eur J Drug Metab Pharmacokin. 31:135–143.
25. M.Mikov, H.Al-Salami, S.Golocorbin-Kon, R.Skrbic, A.Raskovic, J.P.Fawcett. 2008. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokin. 33:137–142.
26. M.Mikov, J.P.Fawcett, K.Kuhajda, S.Kevresan. 2006. Pharmacology of bile acids and their derivatives:Absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokin. 31:237–251.
27. A.Mooranian, R.Negrulj, N.Chen-Tan, H.S.Al-Sallami, Z.Fang, T.Mukkur,. 2014a. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 8:1221–1230.
28. A.Mooranian, R.Negrulj, N.Chen-Tan, M.Fakhoury, F.Arfuso, F.Jones, H.Al-Salami. 2014b. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 1–8.
29. A.Mooranian, R.Negrulj, N.Chen-Tan, G.F.Watts, F.Arfuso, H.Al-Salami. 2014c. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther. 8:1673–1683.
30. B.S.Nayak, S.K.Ghosh K.T.B.Patro. 2009. Preparation and characterization of famotidine microcapsule employing mucoadhesive polymers in combination to enhance gastro retention for oral delivery. Int J Pharm Sci. 1:112–120.
31. A.K.Nayak, M.S.Hasnain, S.Beg M.I.Alam. 2010. Mucoadhesive beads of gliclazide:Design, development, and evaluation. Science Asia. 36:319–325.
32. R.Negrulj, A.Mooranian, N.Chen-Tan, H.S.Al-Sallami, M.Mikov, S.Golocorbin-Kon,. 2015. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 1–8.
33. S.Prajapati P.Tripathi U.Ubaidulla, V.Anand. 2008. Design and development of gliclazide mucoadhesive microcapsules:in vitro and in vivo evaluation. AAPS PharmSciTech. 9:224–230.
34. V.D.Prajapati, K.H.Mashru, H.K.Solanki, G.K.Jani. 2013. Development of modified release gliclazide biological macromolecules using natural biodegradable polymers. Int J Biol Macromol. 55:6–14.
35. A.J.Ribeiro C.Silva, D.Ferreira, F.Veiga. 2005. Chitosan-reinforced alginate microspheres obtained through the emulsification/internal gelation technique. Eur J Pharma Sci. 25:31–40.
36. A.M.Rokstad, I.Lacík, P.De Vos, B.L.Strand. 2014. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev. 67–68:111–130.
37. B.Sarmento, D.Ferreira, F.Veiga, A.Ribeiro. 2006. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym. 66:1–7.
38. C.Sartori, D.S.Finch, B.Ralph, K.Gilding. 1997. Determination of the cation content of alginate thin films by FTi.r. spectroscopy. Polymer. 38:43–51.
39. S.Takka, A.G.Cali. 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17:23–29.
40. M.A.Tormo, M.A.Zubeldia, J.L.Montero, J.E.Campillo. 1989. Gliclazide increases glucose utilization by rat intestine in vitro. Diabete Metab. 15:170–175.
41. K.Tsutsumi, S.K.Li, R.V.Hymas, C.L.Teng, L.G.Tillman, G.E.Hardee,. 2008. Systematic studies on the paracellular permeation of model permeants and oligonucleotides in the rat small intestine with chenodeoxycholate as enhancer. J Pharm Sci. 97:350–367.
42. Y.J.Wang. 2000. Development of new polycations for cell encapsulation with alginate. Mater Sci Eng C. 13:59–63.
43. T.W.Wong, L.W.Chan, S.B.Kho, P.W.Sia Heng. 2002. Design of controlled-release solid dosage forms of alginate and chitosan using microwave. J Control Release. 84:99–114.
44. L.Yang, J.P.Fawcett, J.Ostergaard, H.Zhang, I.G.Tucker. 2012. Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. Mol Pharm. 9:29–36.
45. K.Yasukawa, T.Iida, Y.Fujimoto. 2009. Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage carcinogenesis. J Pharm Pharmacol. 61:1051–1056.